Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...
In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive ...
Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...
-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active ...
Integrating dynamic analysis of serial ctDNA testing to enhance diagnostic and prognostic assessments in patients with metastatic breast cancer.
Adequate CD19-positive cell content is required to reliably identify both dominant and subclonal TP53 mutations. DNA was isolated in parallel from 2 different sample types from this patient: ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results